Latest news with #DDAs
Business Wire
4 days ago
- Business
- Business Wire
Credit Sesame Enlists Green Dot to Enhance Sesame Cash Digital Banking Offering
PROVO, Utah--(BUSINESS WIRE)-- Credit Sesame, one of the first platforms to provide consumers free and ongoing access to their full credit information and profile, is partnering with Green Dot Corporation (NYSE: GDOT) to power and enhance its Sesame Cash smart digital banking service designed to help customers grow their savings. Leveraging Green Dot's embedded finance platform, Arc, Credit Sesame will offer users access to FDIC-insured demand deposit accounts (DDAs) at launch. Following the recent release of Credit Sesame's newest AI-backed management platform, Sesame, additional new services – such as credit-building tools – will also become available to Sesame Cash users as part of this partnership. "This partnership with Green Dot allows us to scale Sesame Cash faster and deliver smarter, more accessible tools to help people transform their finances more quickly." - David Bagatelle, Head of Global Operations and Banking, Credit Sesame Share 'At Credit Sesame, our mission has always been to make financial wellness accessible to everyone by helping consumers grow both their credit and their cash,' said David Bagatelle, Head of Global Operations and Banking, Credit Sesame. 'This partnership with Green Dot allows us to scale Sesame Cash faster and deliver smarter, more accessible tools to help people transform their finances more quickly. With their banking infrastructure and like-minded dedication to financial inclusion, we're excited to deliver an even more powerful Sesame Cash experience that empowers people to take control of their money and their future.' Following the Arc integration, soon-to-come enhancements on the Sesame Cash roadmap include Sesame Credit Builder, which will allow users to build and improve their credit scores with everyday debit purchases – from coffee to subscriptions and more. Activity is reported to the major credit bureaus, helping users improve their credit scores with each payment. 'We are thrilled to partner with Credit Sesame to support, enhance and grow the Sesame Cash banking experience for their users,' said Renata Caine, GM/SVP of Embedded Finance, Green Dot. 'Our shared commitment to improving consumers' financial health through embedded financial services provides a strong foundation for this partnership, and we look forward to continued innovation with Credit Sesame for years to come.' About Credit Sesame Credit Sesame is a leading financial wellness platform dedicated to helping consumers achieve better financial health through cutting-edge technology and data-driven solutions. With a decade of credit expertise and a proven track record of serving over 18 million users, Credit Sesame leverages AI and advanced analytics to empower individuals to improve their credit scores, enhance approval odds, and reduce credit costs. The recently launched Sesame Platform extends this mission by providing financial institutions with a turnkey AI-powered credit intelligence solution. It enables businesses to offer personalized credit and financial wellness experiences, driving deeper customer engagement and growth. Backed by leading institutional and strategic investors, Credit Sesame operates across the U.S. For more information, visit and follow on Instagram, Facebook, X and LinkedIn. About Arc by Green Dot Arc is the embedded finance platform of services featuring all of Green Dot's secure banking and money processing capabilities designed to fuel value, loyalty and growth for consumers and businesses. Arc by Green Dot powers some of the world's most trusted brands and thousands of other businesses with seamless, secure and useful financial tools and experiences. Integrated with Green Dot Bank, Arc provides partners with leading FDIC-insured banking products and tools, plus regulatory and compliance expertise, oversight and support. The Arc platform is cloud-based, modular and scalable by design – configurable to meet a wide range of business needs and goals, and flexible to adapt as our partners grow. Arc's end-to-end banking services are powered by enterprise-grade APIs and offer partners access to comprehensive customer support, fraud protection, the largest retail deposit and ATM network in the U.S., and much more. For more information, visit About Green Dot Green Dot Corporation (NYSE: GDOT) is a financial technology platform and registered bank holding company that builds banking and payment solutions to create value, retain and reward customers, and accelerate growth for businesses of all sizes. For more than two decades, Green Dot has delivered financial tools and services that address the most pressing financial needs of consumers and businesses, and that transform the way people and businesses manage and move money. Green Dot delivers a broad spectrum of financial products to consumers and businesses through its portfolio of brands, including: GO2bank, a leading digital and mobile bank account offering simple, secure and useful banking for Americans living paycheck to paycheck; the Green Dot Network ('GDN') of more than 90,000 retail distribution and cash access locations nationwide; Arc by Green Dot, the single-source embedded finance platform combining all of Green Dot's secure banking and money processing capabilities to power businesses at all stages of growth; rapid! wage and disbursements solutions, providing pay card and earned wage access services to more than 7,000 businesses and their employees; and Santa Barbara Tax Products Group, the company's tax division, which processes more than 14 million tax refunds annually. Founded in 1999, Green Dot has managed more than 80 million accounts to date both directly and through its partners. Green Dot Bank 1 is a subsidiary of Green Dot Corporation and member of the FDIC. For more information about Green Dot's products and services, please visit 1 Green Dot Bank also operates under the following registered trade names: GO2bank, GoBank and Bonneville Bank. All of these registered trade names are used by, and refer to, a single FDIC-insured bank, Green Dot Bank. Deposits under any of these trade names are deposits with Green Dot Bank and are aggregated for deposit insurance coverage up to the allowable limits.
Business Wire
15-07-2025
- Business
- Business Wire
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the launch of an innovative AI-powered module within its proprietary RADR ® platform, designed to predict the activity and efficacy of combination regimens involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) in clinical cancer treatment. With the global market for combination cancer therapies projected to exceed $50 billion by 2030, growing at a CAGR of 8.5%, this module represents a significant advancement in precision oncology, enabling faster, more cost-effective development of tailored therapeutic regimens. Leveraging this AI-driven framework, Lantern Pharma has successfully architected and achieved FDA clearance for a Phase 1B/2 clinical trial in triple-negative breast cancer (TNBC), focusing on a novel DDA-DDRi combination regimen with promising preclinical efficacy. This AI-powered module is a transformative step in our mission to deliver personalized cancer treatments. By leveraging our RADR® platform to analyze complex multi-omics and clinical trial data, we identified optimal DDA-DDRi combinations that guided... Share In a peer-reviewed study published in Frontiers in Oncology, Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review, Lantern Pharma researchers systematically analyzed 221 DDA-DDRi combination-arm clinical trials, involving 22 DDAs and 46 DDRis, to develop this module. The study categorized DDAs into eight subclasses (e.g., alkylating agents, interstrand cross-linkers) and DDRis into 14 subclasses (e.g., PARP, ATR, WEE1 inhibitors). From these, 89 trials with interpretable outcomes were scored for clinical effectiveness, safety, and biomarker-driven responses, providing a robust dataset to train the AI module. 1 Transforming Cancer Combination Therapy Development The new AI module represents a paradigm shift in precision oncology, leveraging machine learning to predict which drug combinations will be most effective for specific patient populations while minimizing toxicity risks. This data-driven approach has already demonstrated its value by successfully guiding the design of Lantern's FDA-cleared Phase 1B/2 clinical trial combining LP-184 with olaparib in triple-negative breast cancer (TNBC). "This AI-powered module is a transformative step in our mission to deliver personalized cancer treatments," said Panna Sharma, CEO & President of Lantern Pharma. "By leveraging our RADR ® platform to analyze complex multi-omics and clinical trial data, we identified optimal DDA-DDRi combinations that guided the development of our TNBC trial. We believe this approach could reduce combination therapy development timelines and costs by one-third compared to traditional methods." The module integrates genomic, transcriptomic, and clinical data to predict synergistic drug interactions, optimize therapeutic outcomes, and identify biomarker-defined patient subpopulations likely to respond to specific combinations. This data-driven approach directly informed the design of Lantern's FDA-cleared Phase 1B/2 trial in TNBC for LP-184 and olaparib, with potential to improve response rates and reduce toxicity. Key insights from the study powering the AI module include: Non-PARP Inhibitor Promise: Non-PARP DDRi combinations, particularly WEE1 inhibitors like adavosertib with platinum agents, showed an 80% positive outcome rate in interstrand cross-linker trials, with strong efficacy in TP53-mutated cancers, directly informing future trial design. Biomarker-Driven Success: Biomarkers such as TP53 mutations and HRD signatures were critical predictors of response, enabling patient stratification to maximize efficacy. Toxicity Mitigation: The use of novel formulations like liposomal doxorubicin in combination regimens reduced cardiotoxicity, providing a safer backbone for combination strategies. Emerging Trends: The analysis emphasizes the patterns in treatment effectiveness, safety, and emerging trends across various cancer types and discusses the potential of biomarkers to guide treatment selection and improve patient outcomes. The module's multi-agentic framework integrates specialized AI agents for data aggregation, drug classification, predictive modeling, biomarker identification, and optimization, creating a dynamic system that is planned to evolve along with new data. The system's continuous learning capability ensures adaptability, enabling Lantern to refine regimens and accelerate future trials across diverse cancer indications. The company is exploring licensing and commercialization opportunities to expand the application of this technology, further revolutionizing combination therapy development. About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI-driven biotechnology company focused on accelerating and optimizing the discovery, development, and commercialization of cancer therapies. Its RADR ® platform leverages artificial intelligence and machine learning to uncover novel therapeutic opportunities, accelerate drug development, and improve patient outcomes. Please find more information at: Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR ® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR ® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR ® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024 under the investor SEC filings tab of our website at or on the SEC's website at Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations. 1 Fontenot R, Biyani N, Bhatia K, Ewesuedo R, Chamberlain M and Sharma P (2025) Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review. Front. Oncol. 15:1577468. doi: 10.3389/fonc.2025.1577468
Forbes
16-04-2025
- Business
- Forbes
The Clearing House Sees Growth In Its Real-Time Payments (RTP)
Real-time payments often travel over fiber optic cables Real-time payments (RTP) in the U.S have been gaining momentum in number of users, number of transactions and the growing maximum size of transactions. Even so, the U.S lags well behind such advanced payments networks as those operated by India and Brazil. In early February The Clearing House (TCH) announced its first $10 million instant payment over the RTP network which had just raised its maximum payment from $1 million to $10 million. The payment was by Computershare, a global transfer agent, from Bank of New York Mellon (BNY) to another financial institution. The average daily volume on the RTP network has jumped this year, from $909.2 million in January to $2.8 billion in mid-March, said Gregory MacSweeney, spokesman for TCH. 'Most of the higher value transactions appear to be corporations moving money between accounts for portfolio rebalancing, cash concentration or paying partners or suppliers. For instance, a large retail chain may move funds from its account in the Midwest, to its main account at headquarters, or move funds to another region.' The average transaction amount during that time was $2,510. Although the RTP network has seen impressive growth, fintech firms that support it have been a little disappointed, said Erika Baumann, director of commercial banking & payments at Datos Insights. 'Alacriti, ACI, Fiserv, Icon Payments and Volante — there's nobody who isn't active in this space,' she said. Vendors are working with their client banks to help them avoid disintermediation, but she hasn't seen a lot of vendors meeting their growth goals. Instead she has seen a lot of disappointment at the pace of adoption, especially with smaller banks. 'That's the result when you don't have mandates from regulators. We kind of go through and get to it when we get to it.' Now RTP is doing great, she added, but it took five years to get to takeoff, and then it doubled volumes quickly. 'It started off slow and then now the volumes are pretty impressive.' RTP faced the same challenge that FedNow, the Federal Reserve's instant payment platform, now faces. Banks are faster to set up facilities to receive instant payments, since receiving is pretty much risk free, but they take longer to start sending. But until a number of banks are sending, what is there for receive-only banks to transact? 'RTP has to overcome that hurdle of getting enough banks sending; FedNow has the same hurdle.' She said FedNow has a fraction of the nation's DDAs participating. Banks have faced technological challenges in going to real-time payments, said Nadish Lad, head of payments at Volante Technologies. It develops systems for real-time payments, including the system BNY Mellon used to send the first $10 million payment over the RTP network. 'To execute that payment, you need every application, every step to be completely real time,' said Nadish. 'Then the next problem is 24x7. These banks have core banking platforms which you can call, check the balance and validate the accounts are all good. But at 10 p.m., the core banking platform shuts down for a refresh, and then starts at 10:30 again.' Not exactly 24x7. If a bank creates a shadow balance, it introduces complexity and added another point of failure. So the bank should modernize its core banking system, but that's like open heart surgery, said Lad. Banks don't have to replace their cores to implement real-time, said Baumann. 'For smaller banks, many are opting to connect through their cores, but non-core providers like Finzly and Volante and Alacriti are largely core agnostic,' she said. 'It is still painful and expensive, but better than a core replacement that can take years, or sometimes a decade.' The big four banks absolutely hold the majority of the market share, she added. 'Not only do they have about half of the total deposits in the U.S., our most recent survey of mid and large corporate indicates that about 67% of these businesses are banking with a big four.' Uneven adoption of real-time payments is a problem for businesses, added Lad. 'If the beneficiary is BNY Mellon, then I know they will receive it in real-time. For the other beneficiaries, I'll have to send by ACH. If I added a day for everyone, no one is going to really benefit.' Lad said banks are still studying real-time payments more than acting. 'Every prospect we talk to in the U.S market asks do you have RTP? We say yes, we have a number of clients who have been live for the last six, seven years in your U.S market. Then, when we ask what are their plans? Oh, they say, we are thinking about it. We will probably look at it next year or the year after that.'
